Recent News

• 09.08.2025 - Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database
• 09.08.2025 - IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants
• 08.26.2025 - iMDx to Participate in NYC Investment Conferences September 8 - 11
• 08.11.2025 - IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch
• 08.04.2025 - iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference
• 07.30.2025 - IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients
• 07.28.2025 - iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025
• 06.23.2025 - iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing
• 06.17.2025 - Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville
• 05.19.2025 - Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology

Recent Filings

• 08.18.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 08.11.2025 - 8-K Current report
• 08.11.2025 - EX-99.1 EX-99.1
• 08.11.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.02.2025 - 8-K Current report
• 06.17.2025 - 8-K Current report
• 06.17.2025 - EX-99.1 EX-99.1